Rapid Readouts

Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study

Presented by Dr. Pankit Vachhani, this updated analysis of the PIONEER trial demonstrated that long-term treatment with avapritinib led to sustained symptom relief, improved quality of life, and maintained a favorable safety profile over approximately 3 years in patients with indolent systemic mastocytosis.

Presented by Dr. Thomas Martin, this IMROZ subgroup analysis demonstrated that adding isatuximab to standard VRd therapy improved progression-free survival and deepened responses in transplant-ineligible patients with newly diagnosed multiple myeloma and 1q21+ status, a high-risk cytogenetic subgroup.

Lydia Scarfò, MD, presented updated phase 1 data from the CaDAnCe-101 study showing that BGB-16673, a novel BTK degrader, demonstrated a manageable safety profile and durable responses in heavily pretreated patients with R/R CLL/SLL, including those with prior BTKi exposure and high-risk mutations.

Jae Park, MD, presents long-term follow-up data from the FELIX study showing sustained remission in a subset of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with obecabtagene autoleucel (obe-cel), with predictors of long-term benefit and no new safety concerns identified.

Presented by Talha Munir, MBChB, PhD, this matching-adjusted indirect comparison demonstrated a significant progression-free survival advantage for zanubrutinib over fixed-duration acalabrutinib plus venetoclax in low-risk, treatment-naive chronic lymphocytic leukemia, with a 36-month progression-free survival rate of 88.5% vs 77%, respectively.

Sacituzumab Govitecan Plus Pembrolizumab vs Chemotherapy Plus Pembrolizumab in Patients With Previously Untreated, PD-L1 Positive, Advanced or Metastatic Triple-Negative Breast Cancer: Primary Results From the Randomized, Phase 3 ASCENT-04/KEYNOTE-D19 Study

Sara Tolaney, MD, MPH, presents primary results from the Phase 3 ASCENT-04/KEYNOTE-D19 study showing that sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival with manageable safety versus chemotherapy plus pembrolizumab in previously untreated PD-L1–positive advanced triple-negative breast cancer.

Chan Y. Cheah, MBBS, DMSc, shares insights on updated results from the phase 1 BGB-11417 trial that were presented at the 2025 EHA Congress in Milan, Italy. The longer follow-up data demonstrate the safety and efficacy of the sonrotoclax plus zanubrutinib combination in patients with relapsed or refractory chronic lympocytic leukemia and small lymphocytic lymphoma.

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, presents results from the phase 3b APPULSE-PNH trial at the 2025 EHA Congress in Milan, Italy. The data demonstrate that, in patients with PNH and hemoglobin ≥10 g/dL who switched from anti-C5 therapy to iptacopan, iptacopan was superior in improving hemoglobin levels from baseline.

Raul Cordoba, MD, PhD, presents results from the phase 1 study of sonrotoclax plus zanubrutinib in relapsed/refractory mantle cell lymphoma, highlighting a favorable safety profile with no tumor lysis syndrome or atrial fibrillation, and promising antitumor activity, including a 78% overall response rate and a 70% complete response rate at the recommended dose of 320 mg.

Carla van Herpen, MD, PhD, presents phase 2 trial results showing that petosemtamab plus pembrolizumab in first-line PD-L1–positive recurrent/metastatic HNSCC achieved a 63% response rate, 9-month median PFS, and 79% 1-year OS, with durable responses and a favorable safety profile.

Brian A. Van Tine, MD, PhD, presents results from the first-in-human Phase 1a trial of BG-68501, a selective CDK2 inhibitor, showing early signs of antitumor activity and a manageable safety profile in heavily pretreated patients with advanced solid tumors, including HR+/HER2– breast cancer and ovarian cancer, supporting continued dose escalation and ongoing enrollment.

Andrew J. Armstrong, MD, ScM, FACP, presented 5-year follow-up data from the ARCHES trial showing that enzalutamide plus androgen-deprivation therapy significantly prolonged overall survival versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer, with consistent benefit across subgroups and no new safety signals.

Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)

Presented by Yelena Y. Janjigian at ASCO 2025, the Phase 3 MATTERHORN study demonstrated that adding durvalumab to FLOT significantly improved event-free survival compared with FLOT alone in patients with resectable gastric and gastroesophageal junction adenocarcinoma, with consistent benefit across subgroups and no new safety concerns.

Martin Dietrich, MD, live from the 2025 ASCO Annual Meeting, presents interim results from the phase 1b DAREONTM-9 study, showing that obrixtamig combined with topotecan is well tolerated and demonstrates promising preliminary efficacy in patients with relapsed or refractory small cell lung cancer, with a confirmed overall response rate of 69%.

Xavier Leleu, MD, PhD, presents primary results from the Phase 3 IRAKLIA study demonstrating noninferior efficacy and a favorable safety profile of subcutaneous versus intravenous isatuximab, both combined with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma.

Alexander Olawaiye, MD, presents results from the phase 3 ROSELLA trial, in which relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer, with a manageable safety profile.

Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing Phase I trial

Jaume Capdevila, MD, PhD, presents results from a phase 1 study showing that obrixtamig monotherapy achieves a 40% response rate and durable disease control with manageable safety in patients with extrapulmonary neuroendocrine carcinoma, particularly those with high DLL3 expression.

Presented by Amer Zeidan, MBBS, this OncLive Rapid Readout highlights results from the phase 2 ASCERTAIN-V trial, in which an all-oral regimen of decitabine-cedazuridine plus venetoclax achieved a 46.5% complete response rate and a median overall survival of 15.5 months in newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

Sarah Sammons, MD, presents updated results from the ReDiscover trial at the 2025 ASCO Annual Meeting in Chicago, demonstrating that the mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant shows promising clinical activity and a manageable safety profile in patients with PIK3CA-mutant HR+/HER2– advanced breast cancer.

Sara Tolaney, MD, MPH, presents results from the phase 3 DESTINY-Breast09 study showing that trastuzumab deruxtecan plus pertuzumab improved progression-free survival vs taxane, trastuzumab and pertuzumab (THP) as a first-line treatment in patients with HER2 positive metastatic breast cancer.

Dr. Lakshmi Nayak presents results from the Phase II PROSPECT study, demonstrating that tirabrutinib monotherapy yields a 66.7% overall response rate and a manageable safety profile in patients with relapsed or refractory primary central nervous system lymphoma, supporting its potential as an effective treatment option in this challenging population.

SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive CLL/SLL

Dr. Constantine S. Tam presents 5-year follow-up results from the SEQUOIA trial, showing that frontline zanubrutinib provides durable progression-free and overall survival with a consistent safety profile in patients with treatment-naïve CLL/SLL, including those with del(17p). Funding supported by BeOne Medicines USA, Inc. Content independently developed by OncLive.